QSS
FATE icon

Quantitative Systematic Strategies’s Fate Therapeutics FATE Stock Holding History

Quantitative Systematic Strategies’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,922
Closed -$601K – 137
2021
Q2 		$601K Sell
6,922
-4,651
-40% -$375K 0.21% 184
2021
Q1 		$954K Buy
11,573
+6,765
+141% +$648K 0.15% 241
2020
Q4 		$437K Sell
4,808
-11,593
-71% -$720K 0.06% 416
2020
Q3 		$656K Buy
16,401
+1,302
+9% +$45.5K 0.11% 266
2020
Q2 		$518K Buy
15,099
+2,623
+21% +$78.2K 0.1% 294
2020
Q1 		$277K Sell
12,476
-3,442
-22% -$87K 0.23% 162
2019
Q4 		$312K Buy
15,918
+5,462
+52% +$86.7K 0.05% 434
2019
Q3 		$162K Buy
+10,456
New +$200K 0.04% 421
2019
Q1 		– Sell
-13,216
Closed -$170K – 486
2018
Q4 		$170K Buy
+13,216
New +$184K 0.04% 549
2018
Q3 		– Sell
-11,350
Closed -$129K – 672
2018
Q2 		$129K Buy
+11,350
New +$125K 0.02% 587

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Quantitative Systematic Strategies's FATE Position: Q3 2021 in Review

Quantitative Systematic Strategies sold out of Fate Therapeutics (FATE) in Q3 2021, closing a stake of 6,922 shares — an estimated $601K sold.

Quantitative Systematic Strategies first reported a position in FATE in Q2 2018 and held it in 10 quarters. The position peaked at $954K in Q1 2021. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

  • Quantitative Systematic Strategies reported no remaining Fate Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 6,922 Fate Therapeutics shares in Q3 2021, an estimated $601K.
  • Quantitative Systematic Strategies first reported a position in Fate Therapeutics in Q2 2018 and held it in 10 quarters.
  • Quantitative Systematic Strategies's Fate Therapeutics position peaked at $954K in Q1 2021.
  • 265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Quantitative Systematic Strategies's 13F filing for Q3 2021, filed 16 Nov 2021.